Loading…
For the year to Mar 2026, sales were ₹43.07 Cr and net profit ₹7.40 Cr.
Company filings, standalone accounts
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 2.04 | 14.42 | 20.98 | 43.07 |
| Expenses | 1.78 | 13.52 | 18.03 | 35.02 |
| Operating Profit | 0.27 | 0.93 | 2.98 | 8.08 |
| OPM % | 13.7% | 6.6% | 14.3% | 18.9% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.04 |
| Interest | 0.03 | 0.19 | 0.33 | 0.36 |
| Depreciation | 0.07 | 0.17 | 0.43 | 0.34 |
| Profit before tax | 0.21 | 0.61 | 2.26 | 7.47 |
| Tax % | 24.9% | 28.2% | 0.9% | 1.2% |
| Net Profit | 0.16 | 0.44 | 2.24 | 7.40 |
| EPS (Rs) | 1.82 | 5.19 | 5.60 | 11.76 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.83 | 0.84 | 4.01 | 6.31 |
| Reserves | 0.15 | 0.54 | 2.77 | 10.06 |
| Borrowings | 1.32 | 3.23 | 1.75 | 5.13 |
| Other Liabilities | 0.93 | 1.49 | 2.28 | 2.89 |
| Total Liabilities | 3.23 | 6.10 | 10.81 | 24.39 |
| Fixed Assets | 0.59 | 1.51 | 1.30 | 1.04 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.01 | 0.02 | 0.06 |
| Other Assets | 2.64 | 4.58 | 9.49 | 23.29 |
| Inventories | 1.34 | 2.53 | 3.29 | 8.94 |
| Trade receivables | 0.96 | 1.56 | 5.65 | 10.62 |
| Cash & equivalents | 0.04 | 0.24 | 0.06 | 1.44 |
| Total Assets | 3.23 | 6.10 | 10.81 | 24.39 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | −0.56 | −1.40 | −3.84 |
| Cash from investing activity | −1.11 | −0.22 | −0.05 |
| Cash from financing activity | 1.85 | 1.45 | 5.28 |
| Net cash flow | 0.18 | −0.17 | 1.39 |
| Capex | 1.07 | 0.20 | 0.06 |
| Free cash flow | −1.64 | −1.61 | −3.91 |
| CFO / OP % | −40.0% | −46.0% | −46.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 170 | 40 | 99 | 91 |
| Inventory days | 736 | 112 | 97 | 143 |
| Days payable | 62 | 29 | 39 | 12 |
| Cash conversion cycle | 845 | 125 | 158 | 222 |
| Working capital days | 296 | 7 | 98 | 105 |
| ROCE % | — | 22.6% | 39.2% | 52.2% |
Himalaya Nutravedics India's sales for the year to Mar 2026 were ₹43.07 Cr.
Net profit for the year to Mar 2026 was ₹7.40 Cr. Earnings per share over the same trailing period were ₹11.76.
Himalaya Nutravedics India reported borrowings of ₹5.13 Cr at Mar 2026, against cash and equivalents of ₹1.44 Cr.
Cash from operations was −₹3.84 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹3.91 Cr.